The Editor's Roundtable: The 10Q Report—Advancing Women's Heart Health Through Improved Research, Diagnosis, and Treatment

Dr. Pepine receives grant/research support from Amarin, Bedminster, New Jersey; Amgen, Thousand Oaks, California; Amorcyte, Allendale, New Jersey; Mesoblast, New York, New York; AstraZeneca Pharmaceuticals, Wilmington, Delaware; Baxter Healthcare, Deerfield, Illinois; Cytori Therapeutics, San Diego,...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2013-11, Vol.112 (10), p.1676-1687
Main Authors: Friedewald, Vincent E., MD, Hayes, Sharonne N., MD, Pepine, Carl J., MD, Roberts, William C., MD, Wenger, Nanette K., MD
Format: Article
Language:English
Subjects:
Biomedical Research - standards
Biomedical Research - trends
Cardiology - methods
Cardiovascular
Cardiovascular disease
Cardiovascular Diseases - diagnosis
Cardiovascular Diseases - therapy
Disease Management
Female
Gender differences
Humans
Medical research
Mortality
Physicians
Women's Health
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dr. Pepine receives grant/research support from Amarin, Bedminster, New Jersey; Amgen, Thousand Oaks, California; Amorcyte, Allendale, New Jersey; Mesoblast, New York, New York; AstraZeneca Pharmaceuticals, Wilmington, Delaware; Baxter Healthcare, Deerfield, Illinois; Cytori Therapeutics, San Diego, California; Daiichi Sankyo, Parsippany, New Jersey; Gambro, Lakewood, Colorado; Genetech, San Francisco, California; GlaxoSmithKline, Philadelphia, Pennsylvania; Eli Lilly, Indianapolis, Indiana; Medtronic, Minneapolis, Minnesota; National Institutes of Health/National Heart Blood and Lung Institute, Bethesda, Maryland; and Sanofi-Aventis, Bridgewater, New Jersey and is a consultant for Amarin, Eli Lilly, Mesoblast, and SLACK, Thorofare, New Jersey. Dr. Wenger receives research grants/contracts from and is part of Trial Steering Committee/Trial Adjudication Committee/Trial Data Safety and Monitoring Board of Abbott Laboratories, Abbott Park, Illinois; Gilead Sciences, Foster city, California; Merck, Whitehouse Station, New Jersey; National Heart and Blood Institute, Bethesda, Maryland; and Pfizer, New York, New York and is a consultant for Abbott Women's Advisory Board, Aboot Park, Illinois; Amgen, Thousand Oaks, California; AstraZeneca, Bridgewater, New Jersey; Gilead Sciences; Janssen, Titusville, New Jersey; Merck; and Pfizer.
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2013.09.003